Showing 1,981 - 2,000 results of 103,350 for search '(( 2 fold decrease ) OR ( 5 ((step decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.64s Refine Results
  1. 1981
  2. 1982

    Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression. by Megan Stevens (3964886)

    Published 2019
    “…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
  3. 1983
  4. 1984

    Decreased bleomycin-induced apoptosis in hTERT transfected MLE cells. by Nissim Arish (736264)

    Published 2015
    “…(B) Flow cytometry analysis demonstrating decreased Annexin V staining in bleomycin-treated hTERT<sup>+</sup> compared to hTERT<sup>ctrl</sup> cells. …”
  5. 1985
  6. 1986

    Decreased self-renewal capacity associated with senescence was prevented in human MSCs following treatment with Ki16425, an LPA<sub>1</sub>/LPA<sub>3</sub> antagonist. by Masahiko Kanehira (183764)

    Published 2012
    “…Fold-change represents decrease in band intensity of Ki16425 treatment for 18 days compared with a control treatment for the same period of time. …”
  7. 1987
  8. 1988
  9. 1989

    Adjustment step size. by Qingnan Ji (22662198)

    Published 2025
    “…Integration efficiency increases by 18.7%, and computational complexity is significantly reduced, with average computation time decreased by 15.4%. User satisfaction also improves, with a 19.5% increase in experience ratings. …”
  10. 1990
  11. 1991
  12. 1992
  13. 1993
  14. 1994
  15. 1995
  16. 1996
  17. 1997
  18. 1998

    Pharmacodynamic Profile of CCX168 in Healthy Human Volunteers. by Pirow Bekker (392139)

    Published 2016
    “…CD11b upregulation was diminished in both blood samples from CCX168 subjects with a 10-fold decrease in C5a potency exhibited in the 12-hour samples.…”
  19. 1999
  20. 2000

    6-OHDA-treated monkeys have decreased PGP9.5-ir in cardiac nerve bundles and fibers. by Valerie Joers (319079)

    Published 2014
    “…<p>(<b>A–D</b>) Microphotographs of PGP9.5-positive nerve bundles (<b>A,B</b>) and fibers (<b>C,D</b>) in control and 6-OHDA-treated animals. …”